spacer
home > ict > autumn 2016 > what is the risk?
PUBLICATIONS
International Clinical Trials

What Is The Risk?

Access to high-quality, real time data is the driver behind risk-based monitoring (RBM) – a methodology used to enhance subject safety and data quality, and to deliver significant efficiency benefits. An RBM approach replaces the in-person, 100% source data verification (SDV) process based on the identification of risks and issues. Its use in clinical trials is increasing as sponsors begin to realise the potential to improve the quality of data while, at the same time, reducing total trial costs by an estimated15-20% (1). This approach is also in line with the push from regulatory authorities in the US and EU for targeted monitoring, as it is more effective than spreading resources equally across all sites.

However, managing and analysing all clinical data during the study – to identify potential current issues and future risks – is a complex speciality, which becomes particularly challenging in global, multi-site trials. Large pharmaceutical companies and CROs may have entire departments devoted to this, but that kind of scope and expertise is expensive and, for many small- and midsized biopharmaceutical and device organisations developing a product on a budget, it simply may not be an option.

Aligning these smaller teams with affordable and robust technologies, which enable the adoption of a risk-based approach to study monitoring, creates cost efficiencies that can significantly benefit them without compromising data value or patient safety.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Greg Ambra is Vice President of Clinical Operations at DZS Clinical Services. With nearly 20 years of experience in the clinical research industry, he has held strategic leadership positions in various sponsor and CRO companies. Greg has led DZS Clinical Services since 2012, and earned his Master’s degree in Medical Sciences from Boston University, US.

As Senior Director of Biostatistics, Jean Battikha has worked in the pharma industry as a statistician for nearly 40 years. He has been involved in the design, analysis and reporting of many clinical trials across several therapeutic areas, as well as with many NDA submissions in both the US and EU.
spacer
Greg Ambra
spacer
spacer
spacer
Jean Battikha
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 
Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement